87 related articles for article (PubMed ID: 29698702)
21. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
23. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
24. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity.
Jin ZH; Furukawa T; Waki A; Akaji K; Coll JL; Saga T; Fujibayashi Y
Biol Pharm Bull; 2010; 33(3):370-8. PubMed ID: 20190395
[TBL] [Abstract][Full Text] [Related]
25. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
26. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
[TBL] [Abstract][Full Text] [Related]
27. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
28. Effective suppression of C5a-induced proinflammatory response using anti-human C5a repebody.
Hwang DE; Choi JM; Yang CS; Lee JJ; Heu W; Jo EK; Kim HS
Biochem Biophys Res Commun; 2016 Sep; 477(4):1072-1077. PubMed ID: 27416759
[TBL] [Abstract][Full Text] [Related]
29. A repeat protein-based DNA polymerase inhibitor for an efficient and accurate gene amplification by PCR.
Hwang DE; Shin YK; Munashingha PR; Park SY; Seo YS; Kim HS
Biotechnol Bioeng; 2016 Dec; 113(12):2544-2552. PubMed ID: 27241141
[TBL] [Abstract][Full Text] [Related]
30. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
31. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
33. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
35. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
[TBL] [Abstract][Full Text] [Related]
36. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
37. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop.
Yang Z; Guo L; Liu D; Sun L; Chen H; Deng Q; Liu Y; Yu M; Ma Y; Guo N; Shi M
Oncotarget; 2015 Mar; 6(7):5072-87. PubMed ID: 25669984
[TBL] [Abstract][Full Text] [Related]
38. In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor.
Kang HB; Rim HK; Park JY; Choi HW; Choi DL; Seo JH; Chung KS; Huh G; Kim J; Choo DJ; Lee KT; Lee JY
Bioorg Med Chem Lett; 2012 Jan; 22(2):1198-201. PubMed ID: 22177784
[TBL] [Abstract][Full Text] [Related]
39. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
[TBL] [Abstract][Full Text] [Related]
40. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Hwang HY; Kim IS; Kwon IC; Kim YH
J Control Release; 2008 May; 128(1):23-31. PubMed ID: 18374444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
